GlassScriptPhysician profile
Karla Avila
NPI 1124656442
$2,040.93
in general payments reported to CMS, 2019-2025
21 companies · $800 in 2025
The $800 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.72 · 2023: $69.71 · 2024: $1,160 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,029.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,029.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $628.27 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Boston Scientific Corporation | $279.03 | 2024 | Ams 700 |
| Pfizer INC. | $142.54 | 2023-2025 | |
| Cvrx, INC. | $131.99 | 2025 | Barostim Neo System |
| Lilly USA, LLC | $113.93 | 2024-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $112.47 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
| Teva Pharmaceuticals USA, INC. | $109.79 | 2023-2025 | Austedo Xr, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $74.43 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $70.04 | 2023-2025 | Ubrelvy |
| Novartis Pharmaceuticals Corporation | $52.00 | 2024 | |
| Mdd US Operations, LLC | $50.79 | 2024 | Gocovri |
| Medtronic, INC. | $46.66 | 2025 | Inceptiv |
| Kyowa Kirin, INC. | $36.82 | 2024 | Nourianz |
| Hologic Sales and Service, LLC | $36.55 | 2025 | Aptima |
| Edwards Lifesciences Corporation | $32.29 | 2025 | Sapien 3 Ultra Resilia |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $24.11 | 2025 | Freestyle Libre 3 |
| Amgen INC. | $20.17 | 2024 | Krystexxa |
| Glaxosmithkline, LLC. | $19.23 | 2024 | Arexvy, Trelegy Ellipta |
| Ipsen Biopharmaceuticals, INC | $17.44 | 2023 | Dysport |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.86 | 2024 | Ofev |
| Axsome Therapeutics, INC. | $14.80 | 2025 | Symbravo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karla Avila listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.